{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T14:11:57Z","timestamp":1708006317298},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,6,27]],"date-time":"2007-06-27T00:00:00Z","timestamp":1182902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s11899-007-0025-z","type":"journal-article","created":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T04:42:55Z","timestamp":1182832975000},"page":"183-189","source":"Crossref","is-referenced-by-count":1,"title":["New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia"],"prefix":"10.1007","volume":"2","author":[{"given":"Deborah A.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,27]]},"reference":[{"key":"25_CR1","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","volume":"91","author":"S. Faderl","year":"1998","unstructured":"Faderl S, Kantarjian HM, Talpaz M, Estrov Z: Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998, 91:3995\u20134019.","journal-title":"Blood"},{"key":"25_CR2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.seminhematol.2006.01.007","volume":"43","author":"R.A. Larson","year":"2006","unstructured":"Larson RA: Management of acute lymphoblastic leukemia in older patients. Semin Hematol 2006, 43:126\u2013133.","journal-title":"Semin Hematol"},{"key":"25_CR3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"J.D. Rowley","year":"1973","unstructured":"Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature 1973, 243:290\u2013293.","journal-title":"Nature"},{"key":"25_CR4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"G.Q. Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 1990, 247:824\u2013830.","journal-title":"Science"},{"key":"25_CR5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","volume":"344","author":"N. Heisterkamp","year":"1990","unstructured":"Heisterkamp N, Jenster G, ten Hoeve J, et al.: Acute leukaemia in bcr\/abl transgenic mice. Nature 1990, 344:251\u2013253.","journal-title":"Nature"},{"key":"25_CR6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"T.G. Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079\u20131082.","journal-title":"Science"},{"key":"25_CR7","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603","volume":"86","author":"J.W. Voncken","year":"1995","unstructured":"Voncken JW, Kaartinen V, Pattengale PK, et al.: BCR\/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 1995, 86:4603\u20134611.","journal-title":"Blood"},{"key":"25_CR8","first-page":"1269","volume":"12","author":"T. Tauchi","year":"1998","unstructured":"Tauchi T, Okabe S, Miyazawa K, Ohyashiki K: The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells. Int J Oncol 1998, 12:1269\u20131276.","journal-title":"Int J Oncol"},{"key":"25_CR9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","volume":"86","author":"T. Skorski","year":"1995","unstructured":"Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al.: Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995, 86:726\u2013736.","journal-title":"Blood"},{"key":"25_CR10","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.4049\/jimmunol.159.10.4720","volume":"159","author":"S.K. Chai","year":"1997","unstructured":"Chai SK, Nichols GL, Rothman P: Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997, 159:4720\u20134728.","journal-title":"J Immunol"},{"key":"25_CR11","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"R.L. Ilaria Jr","year":"1996","unstructured":"Ilaria RL Jr, Van Etten RA: P210 and P190 BCR\/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996, 271:31704\u201331710.","journal-title":"J Biol Chem"},{"key":"25_CR12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428190009148847","volume":"36","author":"S. Faderl","year":"2000","unstructured":"Faderl S, Kantarjian HM, Thomas DA, et al.: Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000, 36:263\u2013273.","journal-title":"Leuk Lymphoma"},{"key":"25_CR13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0889-8588(05)70198-2","volume":"15","author":"J.P. Radich","year":"2001","unstructured":"Radich JP: Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001, 15:21\u201336.","journal-title":"Hematol Oncol Clin North Am"},{"key":"25_CR14","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","volume":"100","author":"H. Dombret","year":"2002","unstructured":"Dombret H, Gabert J, Boiron JM, et al.: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial. Blood 2002, 100:2357\u20132366.","journal-title":"Blood"},{"key":"25_CR15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2403683","volume":"19","author":"F. Pane","year":"2005","unstructured":"Pane F, Cimino G, Izzo B, et al.: Significant reduction of the hybrid BCR\/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2005, 19:628\u2013635.","journal-title":"Leukemia"},{"key":"25_CR16","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/blood.V79.11.3067.3067","volume":"79","author":"A.J. Barrett","year":"1992","unstructured":"Barrett AJ, Horowitz MM, Ash RC, et al.: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992, 79:3067\u20133070.","journal-title":"Blood"},{"key":"25_CR17","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood.V85.11.3353.bloodjournal85113353","volume":"85","author":"N.J. Chao","year":"1995","unstructured":"Chao NJ, Blume KG, Forman SJ, Snyder DS: Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995, 85:3353\u20133354.","journal-title":"Blood"},{"key":"25_CR18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.bmt.1703899","volume":"31","author":"I. Avivi","year":"2003","unstructured":"Avivi I, Goldstone AH: Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant 2003, 31:623\u2013632.","journal-title":"Bone Marrow Transplant"},{"key":"25_CR19","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T. Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, et al.: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000, 289:1938\u20131942.","journal-title":"Science"},{"key":"25_CR20","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2002.20.6.1692","volume":"20","author":"M.C. Heinrich","year":"2002","unstructured":"Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002, 20:1692\u20131703.","journal-title":"J Clin Oncol"},{"key":"25_CR21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","volume":"347","author":"J.F. Apperley","year":"2002","unstructured":"Apperley JF, Gardembas M, Melo JV, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481\u2013487.","journal-title":"N Engl J Med"},{"key":"25_CR22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"B.J. Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038\u20131042.","journal-title":"N Engl J Med"},{"key":"25_CR23","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"O.G. Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965\u20131971.","journal-title":"Blood"},{"key":"25_CR24","first-page":"4674","volume":"9","author":"H. Pfeifer","year":"2003","unstructured":"Pfeifer H, Wassmann B, Hofmann WK, et al.: Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003, 9:4674\u20134681.","journal-title":"Clin Cancer Res"},{"key":"25_CR25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/10428190310001625728","volume":"45","author":"J.F. Leis","year":"2004","unstructured":"Leis JF, Stepan DE, Curtin PT, et al.: Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 2004, 45:695\u2013698.","journal-title":"Leuk Lymphoma"},{"key":"25_CR26","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"D.A. Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396\u20134407.","journal-title":"Blood"},{"key":"25_CR27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M. Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460\u2013466.","journal-title":"J Clin Oncol"},{"key":"25_CR28","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","volume":"108","author":"B. Wassmann","year":"2006","unstructured":"Wassmann B, Pfeifer H, Goekbuget N, et al.: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006, 108:1469\u20131477.","journal-title":"Blood"},{"key":"25_CR29","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2004-09-3785","volume":"105","author":"S. Lee","year":"2005","unstructured":"Lee S, Kim YJ, Min CK, et al.: The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005, 105:3449\u20133457.","journal-title":"Blood"},{"key":"25_CR30","doi-asserted-by":"crossref","first-page":"87a","DOI":"10.1182\/blood.V108.11.87.87","volume":"108","author":"D.A. Thomas","year":"2006","unstructured":"Thomas DA, Kantarjian HM, Cortes J, et al.: Outcome with the hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) [abstract]. Blood 2006, 108:87a\u201388a (Abstract 284).","journal-title":"Blood"},{"key":"25_CR31","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","volume":"109","author":"A. Labarthe de","year":"2007","unstructured":"de Labarthe A, Rousselot P, Huguet-Rigal F, et al.: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007, 109:1408\u20131413.","journal-title":"Blood"},{"key":"25_CR32","doi-asserted-by":"crossref","first-page":"856a","DOI":"10.1182\/blood.V98.5.1302","volume":"98","author":"A.H. Goldstone","year":"2001","unstructured":"Goldstone AH, Prentice HG, Durrant J, et al.: Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Results from the international ALL trial (MRC UKALLXII\/ECOG E2993) [abstract]. Blood 2001, 98:856a (Abstract 3556).","journal-title":"Blood"},{"key":"25_CR33","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","volume":"108","author":"E. Jabbour","year":"2006","unstructured":"Jabbour E, Cortes J, Kantarjian HM, et al.: Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006, 108:1421\u20131423.","journal-title":"Blood"},{"key":"25_CR34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","volume":"106","author":"B. Wassmann","year":"2005","unstructured":"Wassmann B, Pfeifer H, Stadler M, et al.: Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005, 106:458\u2013463.","journal-title":"Blood"},{"key":"25_CR35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bbmt.2004.09.004","volume":"10","author":"P. Anderlini","year":"2004","unstructured":"Anderlini P, Sheth S, Hicks K, et al.: Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation [letter]. Biol Blood Marrow Transplant 2004, 10:883\u2013884.","journal-title":"Biol Blood Marrow Transplant"},{"key":"25_CR36","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","volume":"109","author":"P.A. Carpenter","year":"2007","unstructured":"Carpenter PA, Snyder DS, Flowers ME, et al.: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791\u20132793.","journal-title":"Blood"},{"key":"25_CR37","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.leu.2404320","volume":"20","author":"A. Delannoy","year":"2006","unstructured":"Delannoy A, Delabesse E, Lheritier V, et al.: Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006, 20:1526\u20131532.","journal-title":"Leukemia"},{"key":"25_CR38","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M. Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, et al.: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood 2007, 109:3676\u20133678.","journal-title":"Blood"},{"key":"25_CR39","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/cncr.22631","volume":"109","author":"O.G. Ottmann","year":"2007","unstructured":"Ottmann OG, Wassmann B, Pfeifer H, et al.: Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007, 109:2068\u20132076.","journal-title":"Cancer"},{"key":"25_CR40","doi-asserted-by":"crossref","unstructured":"Pfeifer H, Wassmann B, Pavlova A, et al.: Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007, In press.","DOI":"10.1182\/blood-2006-11-052373"},{"key":"25_CR41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2002-06-1756","volume":"102","author":"W.K. Hofmann","year":"2003","unstructured":"Hofmann WK, Komor M, Wassmann B, et al.: Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 2003, 102:659\u2013661.","journal-title":"Blood"},{"key":"25_CR42","doi-asserted-by":"crossref","first-page":"519a","DOI":"10.1182\/blood.V108.11.519.519","volume":"108","author":"D. Jones","year":"2006","unstructured":"Jones D, Luthra R, Kantarjian H, et al.: Kinase domain point mutations in Ph+ acute lymphoblastic leukemia (ALL) and lymphoid blast crisis of chronic myeloid leukemia (CML) and their emergence following therapy with Bcr-Abl kinase inhibitors [abstract]. Blood 2006, 108:519a (Abstract 1831).","journal-title":"Blood"},{"key":"25_CR43","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M. Azam","year":"2003","unstructured":"Azam M, Latek RR, Daley GQ: Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003, 112:831\u2013843.","journal-title":"Cell"},{"key":"25_CR44","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"M.E. Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876\u2013880.","journal-title":"Science"},{"key":"25_CR45","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A. Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190\u20132196.","journal-title":"Leukemia"},{"key":"25_CR46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"N.P. Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117\u2013125.","journal-title":"Cancer Cell"},{"key":"25_CR47","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J. Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104:3739\u20133745.","journal-title":"Blood"},{"key":"25_CR48","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"N.J. Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, et al.: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690\u2013698.","journal-title":"Blood"},{"key":"25_CR49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"N.P. Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399\u2013401.","journal-title":"Science"},{"key":"25_CR50","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M. Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531\u20132541.","journal-title":"N Engl J Med"},{"key":"25_CR51","first-page":"344s","volume":"24","author":"S. Coutre","year":"2006","unstructured":"Coutre S, Martinelli G, Dombret H, et al.: Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): the CA180015 \u201cSTART-L\u201d study [abstract]. J Clin Oncol 2006, 24:344s (Abstract 6528).","journal-title":"J Clin Oncol"},{"key":"25_CR52","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T. O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500\u20134505.","journal-title":"Cancer Res"},{"key":"25_CR53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E. Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129\u2013141.","journal-title":"Cancer Cell"},{"key":"25_CR54","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H. Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542\u20132551.","journal-title":"N Engl J Med"},{"key":"25_CR55","doi-asserted-by":"crossref","unstructured":"Cortes J, Kantarjian HM, Baccarani M, et al.: A phase 1\/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib [abstract]. Blood 2006, 108:Abstract 168.","DOI":"10.1182\/blood.V108.11.168.168"},{"key":"25_CR56","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S. Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, et al.: NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106:3948\u20133954.","journal-title":"Blood"},{"key":"25_CR57","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"F.J. Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D, et al.: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500\u2013502.","journal-title":"Blood"},{"key":"25_CR58","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood-2004-05-1851","volume":"104","author":"T. O\u2019Hare","year":"2004","unstructured":"O\u2019Hare T, Pollock R, Stoffregen EP, et al.: Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004, 104:2532\u20132539.","journal-title":"Blood"},{"key":"25_CR59","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/1078-0432.CCR-05-0622","volume":"11","author":"T. O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, et al.: Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src\/Abl inhibitors are compatible with imatinib. Clin Cancer Res 2005, 11:6987\u20136993.","journal-title":"Clin Cancer Res"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0025-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-007-0025-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0025-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T13:33:53Z","timestamp":1708004033000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-007-0025-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,27]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1007\/s11899-007-0025-z","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,27]]}}}